MICHELLE GAPAY: Open Payments
NPI 1558549089 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,485 in 25 payments from 8 companies in 2025. Trend: 2023 $18,160 · 2024 $9,882 · 2025 $8,485
Consulting: $3,110Speaker / faculty: $2,663Travel & lodging: $1,132Food & beverage: $980Honoraria: $600
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 12 | $2,891 |
| UCB, Inc. | 4 | $2,243 |
| Janssen Biotech, Inc. | 2 | $1,506 |
| Genentech USA, Inc. | 1 | $750 |
| CATALYST PHARMACEUTICALS, INC. | 2 | $725 |
| Genentech, Inc. | 1 | $145 |
| Biogen, Inc. | 2 | $143 |
| Amgen Inc. | 1 | $82 |
Products named: VYVGART HYTRULO, Evrysdi, AGAMREE, QALSODY, VYVGART, UPLIZNA, Rystiggo.
Industry payments across CA — which companies pay providers there.
